Rybrevant Plus Leclaza Has 'Very Potent Activity' in Lung Cancer Subset

Rybrevant plus Leclaza had promising response and progression-free survival rates in patients with EGFR-mutant non-small cell lung cancer.

Related Keywords

South Korea ,United States ,American ,Byoung Chul Cho ,Yonsei Cancer Center ,American Society Of Clinical Oncology Annual Meeting ,Clinical Oncology Annual ,